South Dakota Investment Council Trims Stock Position in Pfizer Inc. $PFE

South Dakota Investment Council reduced its stake in Pfizer Inc. (NYSE:PFE) by 4.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,280,594 shares of the biopharmaceutical company’s stock after selling 64,614 shares during the quarter. Pfizer accounts for 0.6% of South Dakota Investment Council’s investment portfolio, making the stock its 19th biggest holding. South Dakota Investment Council’s holdings in Pfizer were worth $32,630,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Level Four Advisory Services LLC increased its stake in Pfizer by 6.1% in the 3rd quarter. Level Four Advisory Services LLC now owns 75,357 shares of the biopharmaceutical company’s stock valued at $1,920,000 after buying an additional 4,356 shares during the period. Victory Capital Management Inc. increased its stake in shares of Pfizer by 7.1% during the third quarter. Victory Capital Management Inc. now owns 16,186,751 shares of the biopharmaceutical company’s stock worth $413,395,000 after acquiring an additional 1,071,384 shares during the period. Strive Asset Management LLC purchased a new stake in shares of Pfizer in the third quarter valued at approximately $255,000. Mathes Company Inc. boosted its position in shares of Pfizer by 23.2% during the 3rd quarter. Mathes Company Inc. now owns 49,123 shares of the biopharmaceutical company’s stock worth $1,252,000 after purchasing an additional 9,250 shares in the last quarter. Finally, Focus Partners Advisor Solutions LLC raised its holdings in Pfizer by 4.4% during the third quarter. Focus Partners Advisor Solutions LLC now owns 155,783 shares of the biopharmaceutical company’s stock worth $3,922,000 after purchasing an additional 6,526 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Scotiabank began coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective for the company. Morgan Stanley cut their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Bank of America dropped their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Wolfe Research set a $24.00 price target on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $28.05.

Pfizer Stock Performance

Pfizer stock opened at $27.28 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company has a fifty day moving average price of $26.17 and a two-hundred day moving average price of $25.43. The company has a market cap of $155.12 billion, a PE ratio of 20.06 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period last year, the company earned $0.63 earnings per share. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Major oncology milestones that expand non‑COVID revenue streams — Phase 3 data show PADCEV + Keytruda significantly cut recurrence/death risk and increased complete pathologic responses in muscle‑invasive bladder cancer; Pfizer also won full FDA approval for a BRAFTOVI‑based first‑line regimen in BRAF V600E metastatic colorectal cancer, strengthening its oncology commercial outlook. Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues
• Positive Sentiment: Analyst backing: Argus upgraded Pfizer from “hold” to “buy” with a $35 price target — a notable bullish vote that can attract income and value investors given Pfizer’s high yield. Benzinga
• Positive Sentiment: Dividend/story momentum: coverage highlighting Pfizer as a defensive, high‑yield (6%+) income play supports demand from yield‑seeking funds even as top‑line growth moderates. The Dividend Safe Harbor: 2 Stocks to Watch
• Neutral Sentiment: Analyst debate on valuation and sustainability — several pieces weigh Pfizer’s 11% YTD gain against flat guidance, falling COVID sales and upcoming patent expiries, leaving sentiment mixed on whether current gains are durable. Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
• Neutral Sentiment: Investor commentary & technical interest: social and trading chatter notes a technical rebound, institutional flows and yield attractiveness — supportive background but not an immediate catalyst. Pfizer Stock (PFE) Opinions on Technical Recovery and Pipeline Progress
• Neutral Sentiment: Company presentation/transcript release adds detail but no new headline guidance — useful for modeling but not an immediate market mover. Pfizer Presents at TD Cowen Conference (Transcript)
• Negative Sentiment: Regulatory setback: Pfizer withdrew its Zumrad EMA filing — a direct hit to near‑term approval prospects in that program and a negative signal for that asset’s commercial timing in Europe. Pfizer withdraws Zumrad EMA filing
• Negative Sentiment: CEO publicly flags issues with FDA vaccine leadership — increases perceived regulatory friction and could raise investor concern about approval timelines and government relations. Pfizer CEO flags issues with FDA’s vaccine leadership

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.